{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I%3A+Observational+studies&page=2", "query": { "intervention": "Phase I: Observational studies", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I%3A+Observational+studies&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T17:03:08.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05038150", "title": "Study of SGN1 in Patients With Advanced Solid Tumor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "SGN1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guangzhou Sinogen Pharmaceutical Co., Ltd", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 70, "start_date": "2023-01-16", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 4, "location_summary": "Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038150" }, { "nct_id": "NCT02427217", "title": "An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Congenital Fibrinogen Deficiency" ], "interventions": [ { "name": "FCH", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 22, "start_date": "2015-05-07", "completion_date": "2017-12-06", "has_results": false, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 3, "location_summary": "Aurora, Colorado • Las Vegas, Nevada • Durham, North Carolina", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02427217" }, { "nct_id": "NCT05062785", "title": "Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Out-Of-Hospital Cardiac Arrest", "Healthy" ], "interventions": [ { "name": "Intranasal insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Robert Silbergleit", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-10-04", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05062785" }, { "nct_id": "NCT03050983", "title": "Determination of the Clinical Impact of Continuous Surveillance Monitoring (SM) and Utility of IPI.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Respiratory Depression", "Respiratory Insufficiency" ], "interventions": [ { "name": "IPI", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic - MITG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2017-02-15", "completion_date": "2020-09-10", "has_results": false, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050983" }, { "nct_id": "NCT00785941", "title": "A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "IMC-A12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2006-04", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2011-10-13", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00785941" }, { "nct_id": "NCT01732848", "title": "A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy", "Hepatitis C" ], "interventions": [ { "name": "BMS-986094/INX-08189", "type": "DRUG" }, { "name": "Placebo matching BMS-986094/INX-08189", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2012-11", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-08-15", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 4, "location_summary": "Los Angeles, California • Saint Paul, Minnesota • Knoxville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732848" }, { "nct_id": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer", "Minimal Residual Disease", "Colo-rectal Cancer", "Colon Cancer", "Rectal Cancer", "ctDNA Monitoring", "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Neoplasm, Residual", "Adenocarcinoma of Colon", "Adenocarcinoma" ], "interventions": [ { "name": "ALX148", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-02-15", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868226" }, { "nct_id": "NCT01080521", "title": "Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cognitive Side Effects of Cancer Therapy", "Malignant Ovarian Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Carcinosarcoma", "Ovarian Choriocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Dysgerminoma", "Ovarian Embryonal Carcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Polyembryoma", "Ovarian Sarcoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Cystadenocarcinoma", "Ovarian Teratoma", "Ovarian Yolk Sac Tumor", "Stage I Ovarian Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Cognitive Assessment", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 247, "start_date": "2010-04", "completion_date": "2018-01-27", "has_results": false, "last_update_posted_date": "2018-04-12", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 182, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Burbank, California + 129 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01080521" }, { "nct_id": "NCT04632992", "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable or Metastatic Solid Malignancy" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Investigator's Choice of Chemotherapy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-01-13", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 38, "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Oro Valley", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04632992" }, { "nct_id": "NCT04517838", "title": "Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Adenocarcinoma", "HER2-Positive Breast Carcinoma", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 230, "start_date": "2020-07-31", "completion_date": "2028-07-27", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-29T17:03:08.128Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04517838" } ] }